This grant from the National Cancer Institute aims to develop and validate innovative technologies for improving biospecimen quality in cancer research and clinical care. It targets pre-analytical degradation during sample collection, processing, handling, and storage. This R33 opportunity supports projects with demonstrated feasibility, needing rigorous development and validation for widespread adoption. The goal is to create tools, methods, and instrumentation to preserve sample integrity or establish quality assessment. These technologies will accelerate advancements in cancer biology, detection, diagnosis, treatment, and epidemiology by reducing pre-analytical variations impacting biospecimen utility.
Opportunity ID: 336430
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | RFA-CA-22-004 |
Funding Opportunity Title: | Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Education Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Nov 04, 2021 |
Last Updated Date: | Nov 04, 2021 |
Original Closing Date for Applications: | Sep 22, 2022 |
Current Closing Date for Applications: | Sep 22, 2022 |
Archive Date: | Oct 28, 2022 |
Estimated Total Program Funding: | – |
Award Ceiling: | $300,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | Independent school districts Public housing authorities/Indian housing authorities For profit organizations other than small businesses County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Private institutions of higher education Small businesses Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. |
Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-004.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
Folder 336430 Full Announcement-RFA-CA-22-004 -> RFA-CA-22-004-Full-Announcement.pdf
Packages
Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270550 | Mar 22, 2022 | Sep 22, 2022 | View |
Package 1
Mandatory forms
336430 RR_SF424_5_0-5.0.pdf
336430 PHS398_CoverPageSupplement_5_0-5.0.pdf
336430 RR_OtherProjectInfo_1_4-1.4.pdf
336430 PerformanceSite_4_0-4.0.pdf
336430 RR_KeyPersonExpanded_4_0-4.0.pdf
336430 RR_Budget_3_0-3.0.pdf
336430 PHS398_ResearchPlan_4_0-4.0.pdf
336430 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
336430 RR_SubawardBudget30_3_0-3.0.pdf
336430 PHS_AssignmentRequestForm_3_0-3.0.pdf